(Q38201788)

30 August 2017

title

Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review (English)

1 reference

30 August 2017

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Silvano Sozzani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Giovambattista De Sarro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Piercarlo Sarzi-Puttini

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

9

Aurora Parodi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

4

Silvio Danese

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Vito Annese

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Ornella De Pità

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Sabatino Maione

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Ignazio Olivieri

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

3 April 2014

1 reference

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

287-306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24697663%20AND%20SRC:MED&resulttype=core&format=json

Management of the patient receiving parenteral biologic therapy

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Which are the antibodies to watch in 2013?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Tumor necrosis factor as a therapeutic target of rheumatologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Psoriasis and psoriatic arthritis: clinical features and disease mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Sustained response to anakinra in ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Open label trial of anakinra in active ankylosing spondylitis over 24 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Certolizumab pegol: in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Etanercept: efficacy and safety for approved indications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Follow-on protein products: scientific issues, developments and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Comparability and biosimilarity: considerations for the healthcare provider

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Manufacturing of biodrugs: need for harmonization in regulatory standards

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Post-translational modifications in the context of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The challenge of biosimilars

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The protein science of biosimilars

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Dermal injection of immunocytes induces psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Psoriasis as autoinflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

New insights into the pathogenesis and genetics of psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Pathogenesis and therapy of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Consensus guidelines for the management of plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The concept of psoriasis as a systemic inflammation: implications for disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Advances in the treatment of inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Inflammatory rheumatic disorders and bone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

B effector cells in rheumatoid arthritis and experimental arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Cells of the synovium in rheumatoid arthritis. T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Bi(o)communications among peripheral blood fractions: a focus on NK and NKT cell biology in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Rheumatoid arthritis therapy: advances from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Different effects of biological drugs in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Current concept of spondyloarthritis: special emphasis on early referral and diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

21 January 2018

Early spondyloarthritis.

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The critical role of interleukin-23 in spondyloarthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The genetics of ankylosing spondylitis and axial spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

ASAS/EULAR recommendations for the management of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Safety and efficacy of on-demand versus continuous use of nonsteroidal antiinflammatory drugs in patients with inflammatory arthritis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Biologic therapies for spondyloarthritis: what is new?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Spondyloarthritides: evolving therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Genetics and pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Epidemiology and natural history of inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The IL23 axis plays a key role in the pathogenesis of IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Recent advances in IBD pathogenesis: genetics and immunobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Immune aspects of the pathogenesis of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

New therapies for inflammatory bowel disease: from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Tight control applied to the biological therapy of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Long-term outcome after infliximab for refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment: Table 1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2014.897333